Analysis Tools
immune system
|
• doxycycline treated mice often exhibit focal pneumonia with increased number of intra-alveolar macrophages filling the alveolar spaces, most likely due to airway obstruction by bronchial tumors
|
neoplasm
|
• metastatic foci of adenocarcinomas are occasionally seen in lymph nodes of doxycycline treated mice
|
|
• mice develop lung tumors after 5-6 weeks of doxycycline administration
(J:122849)
• early lesions develop in alveoli after 2-3 weeks of doxycycline administration
(J:122849)
• withdrawal of doxycycline results in decreased proliferation and increased apoptosis of cancer cells and complete tumor regression by 10 days of withdrawal
(J:122849)
• mice treated with the WZ4002 compound show an increase in cell apoptosis and decrease in cell proliferation and regression of tumors
(J:156440)
• mice treated together with the compound EAI045 (an allosteric tyrosine kinase inhibitor) and cetuximab show regression of tumors, however treatment alone with EAI045 has no effect on tumors
(J:235747)
• treatment alone with cetuximab has a minimal effect on tumor regression
(J:235747)
|
|
• typical bronchioloalveolar carcinoma is seen after 4-5 weeks of doxycycline administration
|
|
• invasive peripheral adenocarcinomas with bronchioloalveolar features appears after 7-9 weeks of doxycycline administration and is the dominant histological pattern after 12 weeks of treatment
• early papillary neoplasia in the bronchioles are seen after 2-3 weeks of doxycycline administration which progress into bronchial papillary adenocarcinomas after an additional 6-8 weeks of doxycycline treatment
• both types of lung adenocarcinomas that develop in doxycycline administered mice are resistant to erlotinib treatment
• bronchial tumors that develop in doxycycline administered mice are not sensitive to HKI-272 treatment while peripheral adenocarcinomas show some sensitivity to this treatment
• bronchial and peripheral tumors that develop in doxycycline administered mice are sensitive to combination therapy with HKI-272 and rapamycin
|
respiratory system
|
• doxycycline treated mice often exhibit focal pneumonia with increased number of intra-alveolar macrophages filling the alveolar spaces, most likely due to airway obstruction by bronchial tumors
|
|
• mice develop lung tumors after 5-6 weeks of doxycycline administration
(J:122849)
• early lesions develop in alveoli after 2-3 weeks of doxycycline administration
(J:122849)
• withdrawal of doxycycline results in decreased proliferation and increased apoptosis of cancer cells and complete tumor regression by 10 days of withdrawal
(J:122849)
• mice treated with the WZ4002 compound show an increase in cell apoptosis and decrease in cell proliferation and regression of tumors
(J:156440)
• mice treated together with the compound EAI045 (an allosteric tyrosine kinase inhibitor) and cetuximab show regression of tumors, however treatment alone with EAI045 has no effect on tumors
(J:235747)
• treatment alone with cetuximab has a minimal effect on tumor regression
(J:235747)
|
|
• typical bronchioloalveolar carcinoma is seen after 4-5 weeks of doxycycline administration
|
|
• invasive peripheral adenocarcinomas with bronchioloalveolar features appears after 7-9 weeks of doxycycline administration and is the dominant histological pattern after 12 weeks of treatment
• early papillary neoplasia in the bronchioles are seen after 2-3 weeks of doxycycline administration which progress into bronchial papillary adenocarcinomas after an additional 6-8 weeks of doxycycline treatment
• both types of lung adenocarcinomas that develop in doxycycline administered mice are resistant to erlotinib treatment
• bronchial tumors that develop in doxycycline administered mice are not sensitive to HKI-272 treatment while peripheral adenocarcinomas show some sensitivity to this treatment
• bronchial and peripheral tumors that develop in doxycycline administered mice are sensitive to combination therapy with HKI-272 and rapamycin
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
| lung cancer | DOID:1324 |
OMIM:211980 OMIM:608935 OMIM:612571 OMIM:612593 OMIM:614210 |
J:122849 , J:156440 , J:235747 | |
